Investigational drug · Phase 2
CFI-400945
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia.
Phase 2Last checked: Nov 20, 2026Latest source record: May 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "CFI-400945"
First trial start
2021
Apr 16, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CFI-400945", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- AML
- MDS
- CMML
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "CFI-400945" as an intervention, largest first.
Canadian Cancer Trials GroupResearch network
NCT05601440 · 484 participants (planned) · Start Jun 13, 2023 · Primary completion Dec 31, 2027
Drug: RP-6306; Gemcitabine and 6 more · For: Breast Cancer
Sites: Calgary, Canada; Kelowna, Canada; Vancouver, Canada · 10 sites in all
- Prostate Cancer Biomarker Enrichment and Treatment SelectionActive, not recruiting
Canadian Cancer Trials GroupResearch network
NCT03385655 · 200 participants · Start Aug 1, 2018 · Primary completion Oct 7, 2024
Drug: Adavosertib; Savolitinib and 5 more · For: Prostate Cancer
Sites: Edmonton, Canada; Vancouver, Canada; Halifax, Canada · 11 sites in all
- A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruiting
Treadwell Therapeutics, IncIndustry
NCT04730258 · 72 participants (planned) · Start Apr 16, 2021 · Primary completion Jan 2026
Drug: CFI-400945; Azacitidine · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia and 3 more
Sites: Duarte, California; Sacramento, California; Louisville, Kentucky · 9 sites in all
- CFI-400945 in Patients With Advanced/Metastatic Breast CancerActive, not recruiting
Canadian Cancer Trials GroupResearch network
NCT03624543 · 51 participants · Start Feb 14, 2019 · Primary completion Nov 30, 2026
Drug: CFI-400945 · For: Breast Cancer
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 6 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT01954316 · 46 participants · Start Mar 2014 · Primary completion Jul 2021
Drug: CFI-400945 · For: Advanced Cancer
Sites: Santa Monica, California; Toronto, Canada
- CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerActive, not recruiting
Canadian Cancer Trials GroupResearch network
NCT04176848 · 15 participants · Start Aug 10, 2020 · Primary completion Sep 15, 2022
Drug: CFI-400945; Durvalumab · For: Breast Cancer
Sites: Kelowna, Canada; Hamilton, Canada; Kingston, Canada · 5 sites in all
University Health Network, TorontoAcademic, hospital or other
NCT03187288 · 13 participants · Start May 25, 2018 · Primary completion Jun 30, 2021
Drug: CFI-400945 Fumarate · For: Acute Myeloid Leukemia; Myelodysplastic Syndromes; Relapsed Cancer and 1 more
Sites: Hamilton, Canada; Toronto, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Combination of Radiation Treatment and PLK4-Inhibitor, CFI-400945, Leads to Upregulation of ICAM-1, STAT3 Activation, and Cellular Senescence in TNBC.
Kannampuzha I, Bhat V, Janarthanan S, et al. · Breast Cancer (Auckl) 2026
- CFI-400945 enhances radiosensitivity in colorectal cancer models by promoting mitotic dysregulation and DNA damage-associated apoptosis.
Hwang JW, Gong EY, Cho JM, et al. · Cancer Cell Int 2026
- PLK4 is a potential therapeutic target in nonmelanoma skin cancers: Evidence from molecular and in vivo studies.
Ndiaye MA, Garvey DR, Chhabra G, et al. · Photochem Photobiol 2026
- Polo-like kinase 4 (PLK4) as a therapeutic target in breast cancer.
Parsyan A, Athwal H, Bhat V, et al. · Carcinogenesis 2025
- Polo-like Kinase 4: A Molecular Culprit in Skin Cancer Pathogenesis.
Jaiswal T, Muntaqua D, Ahmad N · Cells 2025
- PLK4 Inhibition as a Strategy to Enhance Non-Small Cell Lung Cancer Radiosensitivity.
Domínguez-Vigil IG, Banik K, Baro M, et al. · Mol Cancer Ther 2025
Also in development for Acute Myeloid Leukemia
- AK117Phase 314 trials
Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- GM-CSFPhase 32 trials
Y-mAbs Therapeutics · Neuroblastoma, Acute Myeloid Leukemia
- HMPL-306Phase 32 trials
Hutchmed · Acute Myeloid Leukemia, Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RVU120SEL120Phase 23 trials
Ryvu Therapeutics SA · Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- IMGN632Phase 22 trials
AbbVie · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.